Following Tuesday's market close, Tetraphase Pharmaceuticals Inc. reported top-line data from the lead-in portion of its two-part phase III IGNITE (Investigating Gram-negative Infections Treated with Eravacycline) 2 trial, showing that both intravenous (I.V.)-to-oral dosing regimens of eravacycline (1.5 mg/kg I.V. followed by 200 mg or 250 mg) compared favorably to comparator drug levofloxacin to treat complicated urinary tract infections (cUTIs).